111 related articles for article (PubMed ID: 36261752)
1. Locoregionally Recurrent Colon Cancer: How Far Have We Come? A Population-Based, Retrospective Cohort Study.
Swartjes H; van Lankveld DWP; van Erning FN; Verheul HMW; de Wilt JHW; Koëter T; Vissers PAJ
Ann Surg Oncol; 2023 Mar; 30(3):1726-1734. PubMed ID: 36261752
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of resection for locoregional recurrence of colon cancer: A retrospective descriptive cohort study.
Chesney TR; Metz JJ; Nadler A; Quereshy FA; Ashamalla S; Acuna SA; Swallow CJ
Eur J Surg Oncol; 2021 Sep; 47(9):2390-2397. PubMed ID: 34034943
[TBL] [Abstract][Full Text] [Related]
3. Curative-intent surgery for isolated locoregional recurrence of colon cancer: Review of the literature and institutional experience.
Wisselink DD; Klaver CEL; Hompes R; Bemelman WA; Tanis PJ
Eur J Surg Oncol; 2020 Sep; 46(9):1673-1682. PubMed ID: 32386750
[TBL] [Abstract][Full Text] [Related]
4. Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II-III Colorectal Cancer: A Population-based Study.
Boute TC; Swartjes H; Greuter MJE; Elferink MAG; van Eekelen R; Vink GR; de Wilt JHW; Coupé VMH
Cancer Res Commun; 2024 Feb; 4(2):607-616. PubMed ID: 38363145
[TBL] [Abstract][Full Text] [Related]
5. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of resection for locoregionally recurrent colon cancer: A systematic review.
Chesney TR; Nadler A; Acuna SA; Swallow CJ
Surgery; 2016 Jul; 160(1):54-66. PubMed ID: 27169604
[TBL] [Abstract][Full Text] [Related]
7. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
[TBL] [Abstract][Full Text] [Related]
8. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
[TBL] [Abstract][Full Text] [Related]
10. Reduced risk of distant recurrence after adjuvant chemotherapy in patients with stage III colon cancer aged 75 years or older.
van Erning FN; Creemers GJ; De Hingh IH; Loosveld OJ; Goey SH; Lemmens VE
Ann Oncol; 2013 Nov; 24(11):2839-44. PubMed ID: 23933560
[TBL] [Abstract][Full Text] [Related]
11. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer.
Bos AC; van Erning FN; van Gestel YR; Creemers GJ; Punt CJ; van Oijen MG; Lemmens VE
Eur J Cancer; 2015 Nov; 51(17):2553-61. PubMed ID: 26360411
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
14. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
15. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.
Christopherson K; Lei X; Barcenas C; Buchholz TA; Garg N; Hoffman KE; Kuerer HM; Mittendorf E; Perkins G; Shaitelman SF; Smith GL; Stauder M; Strom EA; Tereffe W; Woodward WA; Smith BD
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):574-581. PubMed ID: 30851348
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
18. Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer.
Teufel A; Gerken M; Fürst A; Ebert M; Hohenthanner I; Klinkhammer-Schalke M
Eur J Cancer; 2020 Sep; 137():148-160. PubMed ID: 32777714
[TBL] [Abstract][Full Text] [Related]
19. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A
J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer.
Verhoeff SR; van Erning FN; Lemmens VE; de Wilt JH; Pruijt JF
Int J Cancer; 2016 Jul; 139(1):187-93. PubMed ID: 26914273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
